Skip to content

Veradermics MANE Investments - Gross Unrealized Losses

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$3.92B

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's investments - gross unrealized losses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's investments - gross unrealized losses?
Veradermics (MANE) reported investments - gross unrealized losses of $267.4M in Q1 2026.